Knowthestock.com
COLL - Collegium Pharmaceutical Inc

Sell

Weak GrowthStock Price Very High
WeakStrong
WeakStrong

38%

based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 12.97%
Operating Income Growth is -25.91%
Net Income Growth is -52.95%
Earnings Per Share (EPS) Growth is -49.17%
Net Margin is 6.61%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.08
Debt Ratio is 0.86
Current Debt to Net Income Ratio is 26.72
Total Debt to Total Assets Ratio is 0.04
Cash Flow is MODERATE
Cash from Operations Growth is -82.07%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Collegium Pharmaceutical Inc (COLL) - http://www.collegiumpharma.com/
collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Joseph Ciaffoni
Employees - 252
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.